慢性心力衰竭的非特异性免疫调节治疗结果 (ACCLAIM试验):一个安慰剂控制的随机化试验
Guillermo Torre-Amione1, Stefan D Anker, Robert C Bourge
1Heart Transplant Program, Methodist DeBakey Heart Center, Methodist Hospital, Houston, TX 77030, USA. gtorre@tmhs.org
Lancet (London, England)
|January 22, 2008
概括
免疫调节疗法 (IMT) 在特定的慢性心力衰竭患者群体中显示出潜力. 没有先前心肌梗塞或NYHAII类的患者经历了IMT的心血管事件减少.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症调解剂与慢性心力衰竭 (CHF) 的发展和进展有关.
- 研究免疫调节疗法 (IMT) 作为对抗这些病理生理机制的对抗措施.
研究的目的:
- 评估基于设备的非特异性免疫调节疗法 (IMT) 在慢性心力衰竭 (CHF) 患者的疗效.
- 评估IMT对所有原因死亡或心血管住院的综合终点的影响,在患有左心室缩功能障碍的CHF患者中.
主要方法:
- 这是一项双盲,安慰剂控制的试验,涉及2426名NYHA功能类II-IVCHF的患者.
- 患者接受IMT或安慰剂,通过在指定间隔内注入质内注射.
- 主要终点是死亡时间或第一次心血管住院,根据治疗意图进行分析.
主要成果:
- 总体而言,IMT在平均随访10.2个月期间没有显著降低初级终点 (HR 0.92; p=0.22).
- 然而,IMT在特定小组中显示出显著的风险降低:26%的患者没有先前心肌梗塞 (p=0.02) 和39%的NYHAII类患者 (p=0.0003).
结论:
- 非特异性免疫调节疗法 (IMT) 可能为心力衰竭患者中的特定部分提供治疗效益.
- IMT可能是缺乏心肌梗塞史的CHF患者和NYHAII类患者的潜在治疗方法.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...